Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It is named after Dr. James Parkinson, the physician who first described the condition in 1817. Parkinson’s disease develops as a result of the degeneration and loss of dopamine-producing cells in a region of the brain called the substantia nigra.
The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for Parkinson’s disease, but various treatment approaches aim to manage symptoms and improve quality of life. Medications, such as levodopa and dopamine agonists, can help replenish dopamine levels or mimic its effects. Physical therapy, occupational therapy, and speech therapy can assist with mobility, daily activities, and communication. In some cases, deep brain stimulation (DBS) surgery may be recommended to alleviate symptoms.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Parkinson’s Disease.
-
Publication date: Oct 15, 2026 Dr. Jerome Honnorat sits down with host Dr. Divyani Garg ...
-
LRRK2 pathways in PD | Congress 2026
Publication date: Oct 15, 2026 Dr. Sabine Hilfiker addresses with Dr. Tiago Outeiro the slight ... -
Updates in MSA | Congress 2026
Publication date: Oct 15, 2026 Prof. Wassilios Meissner discusses scientific advances in multiple system atrophy, ... -
Parkinson’s disease genetics: What’s new | Congress 2026
Publication date: Oct 15, 2026 Dr. Ignacio Mata discusses with Dr. Divyani Garg the dramatic ... -
Progressing treatments from lab to clinic (Rallying 2026)
Publication date: Oct 15, 2026 This report outlines the scientific process of developing treatments for ... -
Understanding the Parkinson’s Clinical Trial Landscape (Rallying 2026)
Publication date: Oct 15, 2026 This report details the clinical trial landscape for Parkinson’s disease, ... -
The latest chapter in the development of prasinezumab (Rallying 2026)
Publication date: Oct 15, 2026 This report details the 10-year research program surrounding the experimental ... -
Detecting Parkinson’s: Alpha-Synuclein Seeding Assays (Rallying 2026)
Publication date: Oct 15, 2026 This report details the alpha-synuclein seeding assay (SAA), a method ... -
Risk of Schizophrenia Spectrum Disorders Following Parkinson’s Disease: A Nationwide Population-Based Cohort Study.
Publication date: Aug 01, 2026 Psychotic symptoms are common in Parkinson’s disease (PD), yet it ... -
Deep Learning-Based Parkinson’s Disease Classification Using RGB Plantar Pressure Gait Images: A Comparative Study of CNN and Transformer Architectures.
Publication date: Sep 17, 2026 Background/Objectives: Parkinson’s disease (PD) is associated with gait abnormalities that ... -
A Pilot Study of VGGish-CNN as a Model for the Classification of Parkinson’s Disease from a Control Group Using Speech Impairment, Integrated with Explainable Artificial Intelligence.
Publication date: Sep 11, 2026 Introduction: Voice-based digital biomarkers have emerged as a promising, non-invasive ... -
A Hybrid Signal Processing and Deep Learning Framework for Parkinson’s Disease Classification and Determination of ON and OFF Medication Condition.
Publication date: Aug 31, 2026 Parkinson’s disease (PD) is a neurodegenerative disease that can cause ... -
Neuroprotective Effects of Celastrus paniculatus Seed Oil in Rotenoneinduced Parkinson’s Disease in Wistar Rats.
Publication date: Oct 02, 2026 Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by ... -
MRI-derived choroid plexus volume and longitudinal cognitive decline in Parkinson’s disease.
Publication date: Sep 28, 2026 Magnetic resonance imaging (MRI)-derived choroid plexus (CP) volume has been ... -
Walking to the beat: the impact of non-invasive brain stimulation and music on gait in Parkinson’s disease.
Publication date: Sep 23, 2026 Walking impairments in Parkinson’s disease (PD), including reduced speed, cadence, ... -
Harnessing cGAS-STING in neurodegeneration: From mitochondrial DNA leakage and microglial reactivity to species-specific translational barriers.
Publication date: Oct 13, 2026 The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, ... -
GCH1 p.Ser80Asn Confers Risk for Parkinson’s Disease in East Asian Populations.
Publication date: Oct 14, 2026 GCH1 has been implicated in Parkinson’s disease (PD), but its ... -
Neurofilament Light Chain and Mutant Huntingtin Across Huntington’s Disease Integrated Staging System Stages in Huntington Disease: A Cross-Sectional Multimodal Analysis.
Publication date: Oct 14, 2026 The Huntington’s Disease Integrated Staging System (HD-ISS) provides a framework ... -
Restoring Neural Homeostasis via Class II HDAC Modulation: Mechanistic Insights and Therapeutic Opportunities.
Publication date: Oct 15, 2026 Class II histone deacetylases (HDACs) comprise class IIa enzymes HDAC4, ... -
Partner-Specific Audience Design in Parkinson’s Disease: Insights From In-Person and Virtual Modalities.
Publication date: Oct 15, 2026 Successful conversation depends on audience design-tailoring utterances to a partner’s ... -
β-Cyclodextrin-Complexed 1,8-Cineole Attenuates Motor Deficits and Preserves Tyrosine Hydroxylase Immunoreactivity in a Reserpine-Induced Mouse Model of Parkinsonism.
Publication date: Oct 15, 2026 Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by ...